BRPI0516766A - formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso - Google Patents
formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo usoInfo
- Publication number
- BRPI0516766A BRPI0516766A BRPI0516766-3A BRPI0516766A BRPI0516766A BR PI0516766 A BRPI0516766 A BR PI0516766A BR PI0516766 A BRPI0516766 A BR PI0516766A BR PI0516766 A BRPI0516766 A BR PI0516766A
- Authority
- BR
- Brazil
- Prior art keywords
- methylamino
- tetrahydro
- pharmaceutical composition
- polymorphic
- azepino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
FORMAS POLIMóRFICAS E AMORFAS DO SAL DE FOSFATO DE 8-FLúOR-2-{4-¢(METILAMINO)METIL!FENIL}..1 ,3,4,5-TETRAIDRO-6H-AZEPINO¢5,4,3-CD!INDOL-6-ONA COMPOSIçãO FARMACêUTICA, FORMAS DE DOSAGENS E RESPECTIVO USO. A presente invenção refere-se a novas formas polimórficas e amorfas de um sal de 8-flúor-2-{4 ¢(metilamino)metil!fenil}-1 ,3,4,5-tetraidro-6H-azepino¢5,4,3-cd!indol-6-ona representado pela fórmula (1), e a processos para sua preparação. Tais formas polimórficas podem ser um componente de uma composição farmacêutica e podem ser usadas para tratar uma condição doentia de um mamífero mediada pela atividade de poli(ADP- ribose)polimerase incluindo a condição doentia tal como câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61245904P | 2004-09-22 | 2004-09-22 | |
US67929605P | 2005-05-09 | 2005-05-09 | |
PCT/IB2005/002941 WO2006033007A2 (en) | 2004-09-22 | 2005-09-12 | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0516766A true BRPI0516766A (pt) | 2008-09-16 |
Family
ID=35526956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516766-3A BRPI0516766A (pt) | 2004-09-22 | 2005-09-12 | formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso |
Country Status (18)
Country | Link |
---|---|
US (1) | US7268126B2 (pt) |
EP (1) | EP1799685B1 (pt) |
JP (1) | JP2008513436A (pt) |
KR (1) | KR100853601B1 (pt) |
AR (1) | AR051296A1 (pt) |
AT (1) | ATE551345T1 (pt) |
AU (1) | AU2005286191B2 (pt) |
BR (1) | BRPI0516766A (pt) |
CA (1) | CA2581025C (pt) |
ES (1) | ES2382950T3 (pt) |
HK (1) | HK1116483A1 (pt) |
IL (1) | IL181463A (pt) |
MX (1) | MX2007002461A (pt) |
NO (1) | NO337938B1 (pt) |
NZ (1) | NZ554659A (pt) |
RU (1) | RU2355691C2 (pt) |
TW (1) | TWI365188B (pt) |
WO (1) | WO2006033007A2 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05010563A (es) * | 2003-03-31 | 2005-11-23 | Pfizer | Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas. |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
EP1906948A4 (en) * | 2005-07-18 | 2010-03-17 | Bipar Sciences Inc | TREATMENT OF CANCER |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
JP2010502731A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ,インコーポレイティド | Parp阻害剤による脂肪酸合成の阻害、及びその治療方法 |
US8143447B2 (en) * | 2006-09-05 | 2012-03-27 | Bipar Sciences, Inc. | Treatment of cancer |
WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
EP2217244A4 (en) * | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES |
MX2010005222A (es) * | 2007-11-12 | 2010-09-28 | Bipar Sciences Inc | Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales. |
KR20100102637A (ko) * | 2007-12-07 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | 토포이소머라제 억제제 및 parp 억제제의 병용물에 의한 암의 치료 |
WO2009100159A2 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
BR122017013201B1 (pt) | 2009-11-09 | 2018-05-15 | Allergan, Inc. | Composição para a estimulação de crescimento capilar |
WO2011098971A1 (en) | 2010-02-12 | 2011-08-18 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
EP2569307A2 (en) | 2010-05-10 | 2013-03-20 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
CN109602691A (zh) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
WO2016028689A1 (en) | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | High dosage strength tablets of rucaparib |
KR101896567B1 (ko) | 2015-07-23 | 2018-09-07 | 인스티튜트 큐리 | 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도 |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
WO2018140377A1 (en) | 2017-01-24 | 2018-08-02 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018218025A1 (en) * | 2017-05-24 | 2018-11-29 | The Trustees Of The University Of Pennsylvania | Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy |
CA3080657A1 (en) * | 2017-11-03 | 2019-05-09 | Sandoz Ag | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor |
CN111989137A (zh) | 2018-01-05 | 2020-11-24 | 赛博克萨1公司 | 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法 |
US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
EP3765613A1 (en) | 2018-03-13 | 2021-01-20 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
CR20220057A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos |
PE20220563A1 (es) | 2019-07-10 | 2022-04-13 | Cybrexa 2 Inc | Conjugados peptidicos de citotoxinas como terapeuticos |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4100125A1 (en) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph of rucaparib mesylate |
IL297537A (en) | 2020-04-28 | 2022-12-01 | Rhizen Pharmaceuticals Ag | New compounds useful as poly (adp-ribose) polymerase (parp) inhibitors |
WO2022015557A1 (en) | 2020-07-14 | 2022-01-20 | Assia Chemical Industries Ltd | Solid state forms of rucaparib salts |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
AU2022255809A1 (en) | 2021-04-08 | 2023-10-26 | Incozen Therapeutics Pvt. Ltd. | Inhibitors of poly(adp-ribose) polymerase |
WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140936B1 (en) * | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
MXPA05010563A (es) * | 2003-03-31 | 2005-11-23 | Pfizer | Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas. |
CA2533332C (en) * | 2003-07-25 | 2012-01-10 | Cancer Research Technology Limited | Therapeutic compounds |
-
2005
- 2005-09-12 WO PCT/IB2005/002941 patent/WO2006033007A2/en active Application Filing
- 2005-09-12 AU AU2005286191A patent/AU2005286191B2/en active Active
- 2005-09-12 KR KR1020077006422A patent/KR100853601B1/ko active IP Right Grant
- 2005-09-12 AT AT05799991T patent/ATE551345T1/de active
- 2005-09-12 JP JP2007531869A patent/JP2008513436A/ja active Pending
- 2005-09-12 BR BRPI0516766-3A patent/BRPI0516766A/pt not_active Application Discontinuation
- 2005-09-12 MX MX2007002461A patent/MX2007002461A/es active IP Right Grant
- 2005-09-12 EP EP05799991A patent/EP1799685B1/en active Active
- 2005-09-12 NZ NZ554659A patent/NZ554659A/en unknown
- 2005-09-12 CA CA2581025A patent/CA2581025C/en active Active
- 2005-09-12 ES ES05799991T patent/ES2382950T3/es active Active
- 2005-09-12 RU RU2007110026/04A patent/RU2355691C2/ru active
- 2005-09-20 AR ARP050103934A patent/AR051296A1/es unknown
- 2005-09-21 US US11/233,835 patent/US7268126B2/en active Active
- 2005-09-21 TW TW094132634A patent/TWI365188B/zh active
-
2007
- 2007-02-16 NO NO20070920A patent/NO337938B1/no unknown
- 2007-02-20 IL IL181463A patent/IL181463A/en active IP Right Grant
-
2008
- 2008-06-20 HK HK08106859.9A patent/HK1116483A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2581025C (en) | 2011-06-07 |
TWI365188B (en) | 2012-06-01 |
RU2355691C2 (ru) | 2009-05-20 |
ATE551345T1 (de) | 2012-04-15 |
NZ554659A (en) | 2010-08-27 |
WO2006033007A2 (en) | 2006-03-30 |
RU2007110026A (ru) | 2008-10-27 |
AR051296A1 (es) | 2007-01-03 |
KR20070089121A (ko) | 2007-08-30 |
CA2581025A1 (en) | 2006-03-30 |
TW200613305A (en) | 2006-05-01 |
KR100853601B1 (ko) | 2008-08-22 |
ES2382950T3 (es) | 2012-06-14 |
AU2005286191A1 (en) | 2006-03-30 |
US7268126B2 (en) | 2007-09-11 |
NO337938B1 (no) | 2016-07-11 |
US20060100198A1 (en) | 2006-05-11 |
HK1116483A1 (pt) | 2008-12-24 |
WO2006033007A3 (en) | 2006-11-02 |
JP2008513436A (ja) | 2008-05-01 |
NO20070920L (no) | 2007-03-15 |
MX2007002461A (es) | 2008-03-13 |
IL181463A0 (en) | 2007-07-04 |
AU2005286191B2 (en) | 2011-11-17 |
EP1799685B1 (en) | 2012-03-28 |
EP1799685A2 (en) | 2007-06-27 |
IL181463A (en) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516766A (pt) | formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso | |
DOP2010000320A (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
MY163791A (en) | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS cFMS INHIBITORS | |
EA200702044A1 (ru) | Имидазопиридазиновые соединения | |
BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
MY172110A (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
GEP20105054B (en) | Imidazoquinolines as lipid kinase inhibitors | |
DE60315677D1 (de) | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs | |
DE602008003322D1 (de) | Pyrrolo (3, 2, 1-ij) chinolin-4-on-derivate zur behandlung von tuberkulose | |
EA200901505A1 (ru) | 3,6-дизамещенные имидазо[1,2-b]пиридазины и 3,5-дизамещенные пиразоло[1,5-a]пиримидины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
TW200606162A (en) | Pyrazolopyridine derivatives | |
BRPI0517921A (pt) | métodos para preparar compostos de indazol | |
DE602006011609D1 (de) | Organische verbindungen zur behandlung entzündlicher oder allergischer leiden | |
ES2354824T3 (es) | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. | |
MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
CR9591A (es) | Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina | |
TW200730525A (en) | Therapeutic agents | |
TW200716589A (en) | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole | |
SG10201804842WA (en) | Tropomyosin-related kinase (trk) inhibitors | |
WO2006125555A3 (de) | Chinazolinone | |
UY29588A1 (es) | Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina | |
BRPI0417520A (pt) | 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon | |
DE60216745D1 (de) | Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion | |
EP2536720A1 (en) | Triazolo [4, 5 - b]pyridin derivatives | |
BRPI0412809A (pt) | compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |